ArticleCJC pediatric and congenital heart disease2025
Home Milrinone Therapy for Paediatric Advanced Heart Failure Patients: A Canadian Single-Centre Experience.
Article in CJC pediatric and congenital heart disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements and challenges in pediatric dilated cardiomyopathy: a comprehensive review of current approaches and future directions.European journal of pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: End-stage heart failure (ESHF) is the primary reason for heart transplantation in children with cardiomyopathy. Despite optimizing oral heart failure (HF) medications, some paediatric patients progress to ESHF, necessitating mechanical circulatory support and/or transplantation. Continuous milrinone intravenous support has been used to bridge paediatric patients to transplant. This study aimed to review and report the safety and outcomes of our home milrinone therapy (HMT) programme. Methods: This single-centre, retrospective cohort study included paediatric patients discharged on HMT between 2001 and 2022. Data were collected from the SickKids HF Database. Outcomes of interest included frequency and indications for rehospitalization, catheter-related complications, and outcomes at the conclusion of therapy. Results: Thirty-six patients were included, with a median age of 3.6 years and a median weight of 13.1 kg at HMT initiation. HMT was used as a bridge to transplantation (58%) recovery/candidacy (22%), palliative care (17%), and surgical repair (3%). The median duration on HMT was 88 days. Twenty-four patients (67%) were readmitted at least once with a total of 70 admissions, primarily due to central line-related issues (35%) and worsening HF (32%). Among patients discharged as a bridge to transplant, 52% were admitted from home for transplant, whereas 33% required readmission until transplant. No deaths were directly related to HMT. Conclusions: HMT is a safe and effective method for supporting children with ESHF. This therapy allows children to return to their home environment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.